Zacks Investment Research on MSN
MRNA stock jumps on global submissions seeking nod for flu vaccine
Moderna MRNA announced that it submitted regulatory filings seeking approval for its seasonal influenza vaccine mRNA-1010 ...
Moderna MRNA is set to report third-quarter 2025 earnings on Nov. 6, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $860 million and a loss of $2.15 per ...
Two factors often determine stock prices in the long run: earnings and interest rates. Investors can't control the latter, but they can focus on a company's earnings results every quarter. We know ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback